Kintara Therapeutics Announces 1-for-35 Reverse Stock Split in Connection with the Proposed Merger with TuHURA Biosciences
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 16 2024
0mins
Source: PRnewswire
Reverse Stock Split Announcement: Kintara Therapeutics has approved a 1-for-35 reverse stock split of its common stock, effective October 17, 2024, coinciding with its merger with TuHURA Biosciences, which will also change its name and trading symbol to "HURA."
Company Focus and Future Plans: Following the merger, the combined company will focus on developing innovative cancer therapies, including personalized cancer vaccines and antibody drug conjugates, while maintaining a robust pipeline for treating unmet medical needs in oncology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
